Firm seeks effective treatment for Sickle Cell Disease

Oklahoma-based EpimedX may be nearing a treatment for Sicle Cell Disease.
BY REX SMITHERMAN Published: November 27, 2012

“It took us 15 years to think of the idea of how this might work,” Broyles said. “Then another 10 years to show out how it works in principal, and then another 10 years to advance the technology.”

Broyles and EpimedX co-founder Robert Floyd are building the firm's first investment round. The funds will be used to complete preclinical tests and file the drug with the FDA. The next funding round will be for clinical trials.

Thanks to the perseverance of the EpimedX scientists and entrepreneurs, this Oklahoma firm is on a path to bring relief to Sickle Cell Disease sufferers around the world.

Rex Smitherman is interim president and CEO of i2E Inc., a nonprofit corporation that mentors many of the state's technology-based startup companies. i2E receives state appropriations from the Oklahoma Center for the Advancement of Science and Technology. Contact Smitherman at


If both parents have the sickle cell gene, there is a one in four chance of having a baby with Sickle Cell Disease. Eighty-five percent of the approximately 100,000 SCD sufferers in the U.S. are black, 10.6 percent are American Indian, and 4.4 percent are Hispanic-American, Asian-American, or Caucasian.

Trending Now


  1. 1
    'Maze Runner' finds way to box office victory
  2. 2
    The first games that show off iOS 8's graphics are available for download
  3. 3
    Morrison grabs second half winner to hand his side all three points
  4. 4
    Foxes launch comback to secure stunning victory
  5. 5
    WATCH LIVE: Thousands Take To The Streets For The People's Climate March
+ show more